Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aquestive Therapeutics, Inc.
< Previous
1
2
Next >
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
September 27, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
September 09, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
August 22, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
August 14, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 06, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
July 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
July 23, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
June 27, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
June 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
June 18, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
June 03, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
May 28, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
May 09, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
April 29, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
April 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
April 12, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
April 01, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
EBS
GMDA
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
March 25, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
March 19, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
March 19, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
March 14, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 05, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
February 21, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
February 15, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
January 30, 2024
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
December 05, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
November 10, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 06, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
Aquestive Therapeutics Completes $45 Million Debt Refinancing
November 02, 2023
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AQST
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright